Identifying and investigating autoimmune-associated loci and genes |
CRISPR–Cas-mediated genome wide screening30-34
|
All annotated genes can be targeted |
Limited to cell lines |
Can discover cell type-specific effects |
Requires a functional outcome (for example, proliferation) |
CRISPR–Cas-mediated knockout of individual genes37,38
|
Function can be assessed |
Low throughput |
Amenable to primary immune cells |
CRISPR–Cas-mediated activation (CRISPRa) or interference (CRISPRi) of gene expression61,64
|
Easily multiplexable |
Currently limited to cell lines |
Identifying autoimmune regulatory regions |
CRISPR–Cas-mediated activation (CRISPRa) or interference (CRISPRi) of regulatory region60,62,63,65
|
Can test any region of the genome |
Effects might be context-dependent and require multiple cell lines for verification |
CRISPR–Cas-mediated deletion or mutagenesis of regulatory regions55
|
Identifying causal variants |
CRISPR–Cas-mediated mutagenesis of causal variants58
|
Amenable to primary immune cells |
Induced deletions, insertions and substitutions are random and do not recapitulate variant changes |
Some variants cannot be directly targeted |
CRISPR–Cas-mediated homology directed repair80,83
|
Can directly change reference allele to an alternative allele |
Bystander mutations |
CRISPR–Cas-mediated base editing85-90
|
|
Not all mutations are possible |
CRISPR–Cas-mediated prime editing91
|
|
Low efficiency |
Linking variants to causal immune cell types |
CRISPR–Cas-mediated editing paired with single-cell technologies101-105
|
Can be used to directly identify cell populations of interest in rheumatic disorders |
Expensive and prone to drop-out in gene expression |
Can assess the function of a particular variant in a broad range of cell populations simultaneously |